Open Government Portal

Open Data Portal Catalogue Dataset
Found 38172 records

The purpose of this Notice of Amendment is to announce the revised listing for hydrocortisone on the Prescription Drug List (PDL).

Last Updated: Sep 29, 2023
Date Published: Sep 27, 2023
Publisher: Health Canada
Formats: HTML
Keywords: Hydrocortisone notice notice of amendment prescription drug list PDL revised listing

The purpose of this Notice of Amendment is to notify about the addition of hydroquinone or its derivatives to the Prescription Drug List (PDL) for human use when sold in concentrations greater than 2% in topical products.

Last Updated: Sep 29, 2023
Date Published: Sep 27, 2023
Publisher: Health Canada
Formats: HTML
Keywords: Hydroquinone notice notice of amendment prescription drug list PDL revised listing

The purpose of this Notice of Intent to Amend is to notify that, as a result of consultation, Health Canada will switch certain uses of Ibuprofen to nonprescription status for human use by modifying the Human Prescription Drug List (PDL). The Veterinary List will remain unchanged.

Last Updated: Sep 29, 2023
Date Published: Sep 27, 2023
Publisher: Health Canada
Formats: HTML
Keywords: notice of amendment Prescription Drug List PDL Ibuprofen only human PDL revised listing nonprescription status

The purpose of this Notice of Amendment is to notify that Health Canada has revised the listing for levonorgestrel on the Prescription Drug List (PDL). Only the Human part of the PDL was revised; the listing for Veterinary use will remain unchanged.

Last Updated: Sep 29, 2023
Date Published: Sep 27, 2023
Publisher: Health Canada
Formats: HTML
Keywords: Levonorgestrel notice notice of amendment prescription drug list PDL revised listing nonprescription status human use Human Prescription Drug-List Veterinary use unchanged

The purpose of this Notice of Amendment is to announce the revised listing for lovastatin on the Prescription Drug List (PDL). As stated in the Notice of Intent to Amend, posted June 4, 2014, the revision will allow lovastatin to be marketed as a nonprescription product. Only the Human part of the PDL has been revised.

Last Updated: Sep 29, 2023
Date Published: Sep 27, 2023
Publisher: Health Canada
Formats: HTML
Keywords: Lovastatin notice notice of amendment prescription drug list PDL revised listing nonprescription status human use Human Prescription Drug-List Veterinary use unchanged

The purpose of this Notice of Amendment is to notify that Health Canada has revised the listing for Adrenocortical hormones on the Prescription Drug List (PDL) to allow the nonprescription use of Mometasone furoate for the conditions listed below. Only the Human part of the PDL was revised.

Last Updated: Sep 29, 2023
Date Published: Sep 27, 2023
Publisher: Health Canada
Formats: HTML
Keywords: Mometasone furoate notice notice of amendment prescription drug list PDL revised listing nonprescription status human use Human Prescription Drug-List

The purpose of this Notice of Intent to Amend is to notify that, as a result of consultation, Health Canada will switch certain uses of Polymyxin B to prescription status for veterinary use by adding it to the Veterinary Prescription Drug List (PDL).

Last Updated: Sep 29, 2023
Date Published: Sep 27, 2023
Publisher: Health Canada
Formats: HTML
Keywords: Polymyxin B notice notice of amendment prescription drug list PDL prescription status veterinary use Veterinary Prescription Drug-List

The purpose of this Notice of Amendment is to announce the revised listing for Adrenocortical hormones to allow the nonprescription use of triamcinolone acetonide for the conditions listed below. Only the Human part of the PDL has been revised.

Last Updated: Sep 29, 2023
Date Published: Sep 27, 2023
Publisher: Health Canada
Formats: HTML
Keywords: Triamcinolone acetonide notice notice of amendment revised listing Adrenocortical hormones nonprescription use revised human-part-of PDL

A Notice of Compliance is a notification, issued pursuant to paragraph C.08.004(1)(a), indicating that a manufacturer has complied with sections C.08.002 or C.08.003 and C.08.005.1 of the Food and Drug Regulations. Notices of Compliance are issued to a manufacturer following the satisfactory review of a submission.

Last Updated: Sep 29, 2023
Date Published: Sep 27, 2023
Publisher: Health Canada
Formats: HTML
Keywords: NOC Notice of Compliance drug products notification manufacturer complied with sections-C.08.002/C.08.003 Food- and-Drug Regulations review of a submission

The award-winning Health Infobase, a sub-domain of Canada.ca, provides Canadian health information on a wide variety of topics including chronic and infectious diseases, injuries, mental health, health behaviours, health inequalities, consumer products, pesticides, wastewater, wildfires, and many more.
In collaboration with subject matter experts, the Health Infobase team develops easy-to-use data visualizations including interactive and accessible data tools, allowing users to easily access, explore and understand Canadian health information.
By using both filters and free-text search options, users can view data products from different data sources in both static and interactive formats. Many data products have downloadable data sets, which …

Last Updated: Sep 29, 2023
Date Published: Dec 24, 2018
Publisher: Public Health Agency of Canada
Formats: HTML
Keywords: Acute myocardial infarction age standardized rate prevalence incidence mortality asthma chronic obstructive pulmonary disease dementia Alzheimer Alzheimer’s ...